$CTEV

Dalton Travis purchased $250K of CTEV (indirect holdings)

Dalton Travis (Pres., CEO & Executive Chair) purchased 6,450 indirectly-held shares of Claritev Corp (CTEV) at an average of $38.71 ($38.48–$38.81, $0.25M total) across 2 trades over 2026-08-27 to 2026-08-28.

Original reporting
SEC EDGAR · Dalton Travis
Published Aug 31, 2026, 12:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 12:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CTEV
Neutral
medium confidence
Mentioned
$CTEV
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTEVNeutralLow
01

Why it matters

The purchase is modest and does not suggest a material shift in insider sentiment.

02

Market read

A small insider buy with limited trading relevance.

03

What to watch

No 10b5-1 plan; the purchase may reflect personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed today (2026-08-31)

Background

Form 4 filings disclose insider trades; investors monitor them for signals of confidence.

Company-level read

Ticker impact

$CTEVNeutralMedium confidence
Context

CEO Dalton Travis bought 6,450 shares for $249,664, increasing his stake to 52,322 shares.

Expected impact

Minimal short-term price effect; may slightly support bullish sentiment.

Evidence & confidence

The transaction is a routine insider buy under $250K, unlikely to move the stock materially.

Market effects

None; the purchase does not affect the broader sector.

None; limited to the company.

None

Counterpoint

The buy could be a routine portfolio adjustment rather than a strong endorsement.

Key entities

  • Dalton Travis

    President, CEO & Executive Chair of Claritev Corp.

  • Claritev Corp

    US-listed biotech firm (ticker CTEV).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CTEVMedAI 8/10

Claritev Q2 Earnings Call Highlights

Claritev (NYSE:CTEV) reported Q2 No Surprises Act-related revenue growth attributed mainly to one client, with management saying claim mix drove lower charges per claim. Bookings were $30M ACV in Q2 and $74M in H1, exceeding 2025 total and targeting over $100M for FY. FY revenue guidance raised to $1.00B-$1.02B and adjusted EBITDA to $610M-$620M.

$CTEVMed

Claritev Corp (CTEV): Results of Operations and Financial Condition

Claritev Corp (CTEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. E Claritev Corporation Reports Second Quarter 2026 Results – Q2 2026 Revenues of $257.5 million grew 6.6% compared to Q2 2025 – Net Loss of $59.2 million – Adjusted EBITDA of $155.8 million increased 1.1% compared to Q2 2025 (Adjusted EBITDA Margin of 60.5% versus 63.8% in Q2 202